Backgrounds: I labeled orthoiodohippurate (OIH) have been used for renal tubular function study for many years. The β-particle emission associated with the decay of □I not only increases absorbed radiation dose in patients, but also reduces the quality of scintigraphic imaging. Recently, another new radiopharmaceutical □ Tc-MAG□ prepared from INER Mertiatide kit has been developed, and may probably replace some of the applications of □I-OIH for renal tubular function evaluation.
Material & Methods: In this study, 12 normal volunteers (9 males, 3 females; age: 37.0 ± 12.4 years) and 28 (14 males, 14 females; age: 55.5±16.5 years) adults with or highly-suspected renal function disorder (renal stone, chronic renal insufficiency, etc.) were enrolled to compare INER Tc-MAG with I-OIH in the efficacy of effective renal plasma flow determination. Each volunteer or patient was administered 10 mCi of Tc-MAG□ for the first study and 300 μCi of I-OIH for the second study. Dynamic images were collected with a gamma camera for 30 min. In addition, a single blood sample was drawn at 44 min post-injection in each study.
Results: The results reveal a good correlation between these two agents with ERPF calculated by the single blood sampling method (r=0.814).
Conclusions: Through this study, we can confirm the usefulness and the effectiveness of INER Mertiatide kits for clinical evaluation of ERPF by single blood sampling method.

前言：多年來國內核醫界普遍使用碘-I31馬尿酸（碘-131-OlH）進行有效腎血流量之檢查。由於碘-131釋放之加馬射線能量較高，造影效果不佳，且會釋出貝它粒子，使受檢者吸收較高的輻射劑量。國內核能研究所已研發出可供製備鎝-99m-MAG□的組套，用以取代碘-131-OIH。本研究以核研所組套製備鎝-99m-MAG□製劑，對正常人及病患進行有效腎血流量測之臨床可用性評估。
材料與方法：本研究共收集12名正常人（9男，3女;年齡：37.0±12.4歲）及28名經確定或高度懷疑有泌尿道疾患之病患（14男，14女;年齡：55.5±16.5歲）進行研究。所有受試者皆分別接受鎝-99m-MAG 及碘-131-OlH兩種製劑之腎功能檢查，並以單次抽血方式算有效腎血流清除率，以直線迴歸及相關統計法比較鎝-99m-MAC 與碘-131-OlH結果。
結果：研究結果發現以單次抽血方式計算有效腎血流清除率，鎝-99m-MAG 與碘-131-OIH所得結果之直線迴歸函數為OIH=109.25+1.3693xMAG （相關係數r值為0.814）。
結論：研究結果顯示核研所鎝-99m-MAG 製劑以單次抽血方式評估有效腎血流清除率與碘-131-OIH單次抽血方式所得之結果呈現相當好的相關性，支持核研所鎝-99m-MAG□用以評估有效腎血流量的臨床可用性